Oslo University Hospital will initiate a multicentre randomized Phase 2 trial of ILB® in Amyotrophic Lateral Sclerosis (ALS) in early 2026. The study will directly compare ILB® with Riluzole, the current standard of care.
- Patients: 116
- Duration: 12 months
- Design:
- 6-month double-blind randomized phase (Riluzole vs ILB®)
- 6-month open-label extension (all patients receive both ILB® and Riluzole)
The trial will be sponsored by Oslo University Hospital, funded through public research grants, and is restricted to Norwegian residents.
Leadership and Oversight
- Coordinating Investigator: Dr. Angelina Hatlø Maniaol, Senior Consultant Neurologist.
- Drug Supply: Tikomed will provide ILB® and matching placebo for the RCT.
The study has received all necessary regulatory approvals and will begin patient enrollment in Q1 2026. Final results are expected by end of 2028.
About ILB® and Tikomed
ILB® is Tikomed’s investigational therapy for neurodegenerative and degenerative disorders. It is a dextran sulphate with a favorable safety profile and encouraging results from small-scale Phase 2a proof-of-concept ALS studies.
Tikomed, based in Viken, Sweden, is privately owned and focused on advancing breakthrough therapies in neurodegeneration.
About ALS
Amyotrophic Lateral Sclerosis (ALS)—also known as Lou Gehrig’s disease—is a severe, progressive, and ultimately fatal neurodegenerative disorder.
- Global prevalence: 250,000–300,000 people.
- New cases annually: ~60,000.
- Prognosis: Average survival is less than 3 years after diagnosis.
- Core symptoms: Declining motor function, progressing to inability to swallow and breathe.
